 EXETER, N.H.--BUSINESS WIRE--Vapotherm, Inc. NYSE: VAPO, Vapotherm or the Company, a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary unaudited fourth quarter and full year 2020 revenue results. Preliminary revenue for the fourth quarter of 2020 is expected to be approximate 